industries · Pharma & biotech

Your R&D pipeline never trains anyone’s model

Extreme IP confidentiality, data integrity in regulated environments and GDPR on trial data: R&D-grade AI that runs on-premise by default, with nothing leaving your walls.

compliance

Compliance, built into the stack.

Every regulatory demand mapped to a platform capability that ships built in, with nothing to configure.

IP confidentiality

R&D pipelines, preclinical data

RequiresR&D pipelines and preclinical data are the crown jewels; nothing can feed an external model.

HelmcodeOn-premise by default with zero logs: open weights run inside your walls and never train anyone’s model.

GxP / Annex 11

EudraLex Vol. 4, Annex 11 (computerised systems)

RequiresGxP-regulated computerised systems demand data integrity, audit trails and validation (verify applicability per process).

HelmcodeA single auditable stack with documented data flows that you can validate as part of your quality system.

GDPR

Regulation (EU) 2016/679

RequiresTrial and patient data carry special-category protection.

HelmcodeEU-only inference and zero logs, on-premise for the most sensitive datasets.

This page is an informational overview, not legal advice. For your obligations and the risk classification of each system, consult qualified legal counsel. AI Act Guide →

what the agency will look at

What the EMA expects across the product lifecycle.

In September 2024 the EMA set out how it will look at AI from discovery through to post-authorisation. A reflection paper is not law: it states the principles the agency considers relevant to regulatory evaluation, scaled to the regulatory impact and patient risk of each use. Four of them touch the architecture.

01

The duty has a name, and it is yours

A key principle, in the EMA’s own words: the trial sponsor, the applicant or holder of the authorisation, or the manufacturer must ensure every algorithm, model, dataset and data pipeline is fit for purpose. It warns the standard can be stricter than usual data-science practice.

02

A black box has to earn its place

Black-box models are acceptable where you substantiate that interpretable ones perform or hold up worse. Then you owe the architecture, the hyperparameter tuning, training metrics, validation and test results and a monitoring plan, and the EMA suggests discussing the case with it in advance.

03

The weights can carry the data

Large models are at particular risk of memorising what they were trained on, and the conclusion is blunt: if the data are not fit for sharing, anonymise before moving the model to a less secure environment. In that sentence, where a model runs becomes a data-transfer decision.

04

Generated text needs a reviewer

Whatever a model drafts, edits or translates for product information goes under close human supervision, because generative models produce plausible but wrong or incomplete text, and a quality review has to confirm it before a regulator sees it. That is a process, and nobody sells it to you.

EMA · European Medicines Agency "Reflection paper on the use of Artificial Intelligence (AI) in the medicinal product lifecycle", EMA/CHMP/CVMP/83833/2023, 9 September 2024, adopted by the CHMP and the CVMP. A reflection paper states the agency’s considerations, not binding requirements. read the report →

use cases

Your most common use cases.

The cases with the most traction in the sector, each with its own page in detail.

Recommended open models.

A starting point per task type. The full guide maps 80 cases to the open model for each one.

GLM-5.2MIT · 1M ctx
Scientific reasoning over complex documentation, on-premise for confidential IP.
qwen3-embedding + rerankApache 2.0 · embeddings in Helmcode
Semantic search over literature and internal documentation.
DeepSeek V4 FlashMIT · 1M ctx in Helmcode
Volume summarization and extraction across study documentation.

in progressWe are distilling and quantizing these open models into small, tightly specialised versions, trained for one task rather than for all of them. A model like that runs on less hardware, answers faster and fits where the big one does not, your own datacenter included. If you have a process with volume and stable criteria, that is the conversation we want to have with you.

// faq

Questions, answered.

What the sector's technical, compliance and business teams ask.

Does our R&D data train the model?

No. Prompts and outputs are never stored and never used for training (zero logs), and the on-premise deployment runs open weights inside your own walls, so pipelines and preclinical data never leave.

How does this fit GxP data integrity?

GxP-regulated computerised systems (EudraLex Vol. 4, Annex 11) demand data integrity, audit trails and validation. A single auditable stack with documented data flows can be validated as part of your quality system; the applicability to each process is decided by your quality team.

Can everything run on-premise?

Yes, and for pharma R&D it usually does by default. The same models and API run inside your datacenter, the norm for confidential IP and trial data.

Can it search our scientific literature privately?

Yes. qwen3-embedding plus reranking powers semantic search over papers and internal documentation, with GLM-5.2 for reasoning, all inside your perimeter.

// get started

START BURNING TOKENS

Skip the AI infra work. Deploy your first private inference endpoint today.

Flat rate. EU data. OpenAI API compatible.